Having trouble viewing this email? View it as a Web page.

FOR IMMEDIATE RELEASE: Friday, July 29, 2022
Contact: Lynn Hicks | chief of staff | 515-281-6699| lynn.hicks@ag.iowa.gov | 

Miller reaches $2.37 billion agreement with former opioid maker Allergan

Announcement comes after Teva agreement

DES MOINES – Iowa Attorney General Tom Miller and a bipartisan group of AGs announced an agreement in principle to address the opioid crisis for the second time this week. The proposed settlement on important financial terms would require former opioid maker Allergan to pay up to $2.37 billion to participating states and local governments. 

If finalized, the Allergan settlement, together with the Teva Pharmaceuticals settlement announced this week, would provide as much as $6.6 billion nationwide, including for abatement of the crisis. Abbvie, which acquired Allergan in 2020, disclosed the agreement in its earnings announcement Friday.

Both settlements remain contingent on resolution of key issues, including details regarding the settlement structure, which is expected to build on the framework developed in prior nationwide opioid settlements. The parties are also negotiating terms requiring business practice changes and transparency. 

Miller's office led the negotiations with Teva and Allergan.  

"We've worked hard to get the best result for Americans harmed by the opioid crisis, and it's rewarding to take another step in the right direction," Miller said. "We continue to make it a priority to hold manufacturers responsible, while ensuring victims of this epidemic receive the help they need.”

Ireland-based Allergan formerly made Norco- and Kadian-branded and generic opioids. The company sold its generics portfolio, including opioid products, to Teva in 2016. Teva and the AGs announced Tuesday that they had reached an agreement in principle to provide up $4.25 billion to address its part in the opioids crisis. The Teva agreement in principle is contingent, in part, on Allergan reaching its own settlement with the states. 

The coalition of states alleged that Allergan:

• Deceptively marketed opioids by downplaying the risk of addiction, overstating their benefits, and encouraging doctors to treat patients showing signs addiction by prescribing them more opioids; and
• Failed to maintain effective controls to prevent diversion of opioids.

The $2.37 billion figure includes money that Allergan has already agreed to pay under settlements with individual states.

In addition to Iowa, other states taking a leading role in negotiations are California, Illinois, Maryland, Massachusetts, New York, North Carolina, Pennsylvania, Tennessee, Texas, Vermont, Virginia, and Wisconsin. While New York was among the 13 states integral to negotiating this settlement, New York settled separately with Allergan in December 2021 as a part of its trial.